JP2021515005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021515005A5 JP2021515005A5 JP2020545532A JP2020545532A JP2021515005A5 JP 2021515005 A5 JP2021515005 A5 JP 2021515005A5 JP 2020545532 A JP2020545532 A JP 2020545532A JP 2020545532 A JP2020545532 A JP 2020545532A JP 2021515005 A5 JP2021515005 A5 JP 2021515005A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024009405A JP2024038482A (ja) | 2018-03-01 | 2024-01-25 | 標識オキシトシンならびに製造および使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637187P | 2018-03-01 | 2018-03-01 | |
| US62/637,187 | 2018-03-01 | ||
| PCT/US2019/020419 WO2019169342A1 (en) | 2018-03-01 | 2019-03-01 | Labeled oxytocin and method of manufacture and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009405A Division JP2024038482A (ja) | 2018-03-01 | 2024-01-25 | 標識オキシトシンならびに製造および使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515005A JP2021515005A (ja) | 2021-06-17 |
| JP2021515005A5 true JP2021515005A5 (ja) | 2021-11-11 |
| JPWO2019169342A5 JPWO2019169342A5 (ja) | 2022-03-07 |
Family
ID=65763911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545532A Pending JP2021515005A (ja) | 2018-03-01 | 2019-03-01 | 標識オキシトシンならびに製造および使用の方法 |
| JP2024009405A Pending JP2024038482A (ja) | 2018-03-01 | 2024-01-25 | 標識オキシトシンならびに製造および使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009405A Pending JP2024038482A (ja) | 2018-03-01 | 2024-01-25 | 標識オキシトシンならびに製造および使用の方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11970554B2 (ja) |
| EP (1) | EP3759121A1 (ja) |
| JP (2) | JP2021515005A (ja) |
| WO (1) | WO2019169342A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11631208B1 (en) * | 2021-12-22 | 2023-04-18 | RealizeMD Ltd. | Systems and methods for generating clinically relevant images that preserve physical attributes of humans while protecting personal identity |
| US11935238B2 (en) * | 2021-12-22 | 2024-03-19 | RealizeMD Ltd. | Systems and methods for generating clinically relevant images that preserve physical attributes of humans while protecting personal identity |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1936364A (en) | 1930-08-22 | 1933-11-21 | Pfizer Charles & Co | Citrate solutions |
| US2260004A (en) | 1939-11-03 | 1941-10-21 | Pfizer Charles & Co | Stable soluble magnesium acid citrate |
| US2938891A (en) | 1956-03-30 | 1960-05-31 | Roussel Uclaf | Method of making oxytocin and intermediates thereof |
| US3076797A (en) | 1957-07-22 | 1963-02-05 | Roussel Uclaf | Process of producing oxytocin and intermediates obtained thereby |
| DE19627228A1 (de) | 1996-07-05 | 1998-01-08 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| JP2004161664A (ja) | 2002-11-13 | 2004-06-10 | Fancl Corp | プロポリス組成物 |
| WO2004062563A2 (en) * | 2003-01-16 | 2004-07-29 | Université de Lausanne | Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders |
| GB0319119D0 (en) | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
| US7763234B2 (en) | 2004-03-04 | 2010-07-27 | Ge Healthcare As | Pharmaceutical compounds |
| CN101065152A (zh) | 2004-09-29 | 2007-10-31 | 通用电气医疗集团股份有限公司 | 靶向尿激酶纤溶酶原激活物受体的造影剂 |
| AU2007354659B2 (en) | 2007-06-07 | 2014-01-30 | Kyalin Bioscience, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| JP2010085108A (ja) | 2008-09-29 | 2010-04-15 | Nano Factory:Kk | 生体光イメージング用プローブ |
| EP3156078B1 (en) | 2009-04-10 | 2020-03-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fucoidans as ligands for the diagnosis of degenerative pathologies |
| WO2011106732A1 (en) | 2010-02-25 | 2011-09-01 | Wyeth Llc | Pet monitoring of ab-directed immunotherapy |
| US20130130985A1 (en) | 2010-04-01 | 2013-05-23 | Paul Alewood | Oxytocin peptide analogues |
| JP2013230986A (ja) * | 2010-08-25 | 2013-11-14 | Kyorin Pharmaceutical Co Ltd | 新規ヒダントイン誘導体及びそれらを有効成分とする医薬 |
| JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| JP6445861B2 (ja) * | 2014-12-18 | 2018-12-26 | 国立大学法人金沢大学 | オキシトシン検出のためのサンプルの前処理方法 |
| PT3242676T (pt) * | 2015-01-07 | 2023-12-06 | TONIX Pharmaceuticals Holding Corp | Formulações de ocitocina que contém magnésio e métodos de uso |
| CN108697756B (zh) * | 2015-12-02 | 2022-05-27 | 密歇根大学董事会 | Her2肽试剂和方法 |
-
2019
- 2019-03-01 JP JP2020545532A patent/JP2021515005A/ja active Pending
- 2019-03-01 US US16/976,912 patent/US11970554B2/en active Active
- 2019-03-01 EP EP19710979.6A patent/EP3759121A1/en active Pending
- 2019-03-01 WO PCT/US2019/020419 patent/WO2019169342A1/en active Application Filing
-
2024
- 2024-01-25 JP JP2024009405A patent/JP2024038482A/ja active Pending